

Sido Muncul Tbk (SIDO IJ)

Kinerja 6M23 Dibayangi Permintaan yang Melambat

Sepanjang 6M23, SIDO berhasil membukukan kenaikan penjualan sebesar 3% YoY menjadi Rp1,7 triliun dengan Tolak Angin masih menjadi market leader (pangsa pasar 6M23: 73%). SIDO mengalami kerugian selisih kurs yang belum direalisasi pada 6M23 sebesar Rp37 miliar yang dikontribusi oleh Naira Nigeria yang terdepresiasi lebih dari 70% dibandingkan dengan mata uang dunia sehingga membawa laba bersih 6M23 tercatat Rp448 miliar atau tumbuh 1% YoY.

Company Report | August 2, 2023

Berhasil Membukukan Pertumbuhan yang Stabil

- Sepanjang 6M23, SIDO berhasil membukukan kenaikan penjualan sebesar 3% YoY menjadi Rp1,7 triliun (vs 6M22: Rp 1,6 triliun) dengan Tolak Angin masih menjadi market leader (pangsa pasar 6M23: 73% vs 6M22: 71%). SIDO mengalami kerugian selisih kurs yang belum direalisasi pada 6M23 sebesar Rp37 miliar yang dikontribusi oleh Naira Nigeria yang terdepresiasi lebih dari 70% dibandingkan dengan mata uang dunia sehingga membawa laba bersih 6M23 tercatat Rp448 miliar atau tumbuh 1% YoY. Adapun secara kuartalan, pada 2Q23 penjualan SIDO tercatat Rp746 miliar (-18% QoQ; +2,0% YoY) dan laba bersih tercatat Rp148 miliar (-51% QoQ; -2% YoY).
- Di tengah menurunnya beban pokok penjualan pada 2Q23 sebesar 1% YoY, GPM 2Q23 mampu tercatat lebih tinggi yaitu 53% (vs 2Q22: 51%) diikuti oleh OPM 2Q23 yang juga meningkat menjadi 30% (vs 2Q22: 26%) akibat menurunnya beban umum dan administrasi. Namun, pada 2Q23 dari sisi NPM belum mampu tercatat lebih tinggi atau turun menjadi 20% (vs 2Q22: 21%).

Stabilnya Harga Bahan Baku Tampak Pada Gross Margin Tiap Segmen

- Segmen Jamu Herbal dan Suplemen mencatatkan pertumbuhan penjualan sebesar 2% YoY dengan GPM yang tercatat stabil di level 67% pada 6M23 didorong oleh stabilnya harga bahan baku. Pada segmen ini, Esemag mencatatkan pertumbuhan yang kuat dengan penjualan 6M23 tumbuh 125% YoY.
- Dari segmen Makanan dan Minuman, penjualan 6M23 tumbuh 9% YoY diikuti oleh GPM yang mengalami sedikit kenaikan menjadi 31% akibat menurunnya beberapa harga bahan baku. Segmen ini didukung oleh pertumbuhan penjualan dari Produk Ready To Drink (RTD) serta tingginya permintaan pada Kuku Bima Energi di Luar Jawa.
- Namun, segmen Farmasi mencatatkan penurunan penjualan pada 6M23 sebesar 30% YoY yang diiringi oleh menurunnya GPM menjadi 32% (vs 6M22: 40%). Sebagian besar SKU atas obat sirup sudah dapat didistribusikan kembali pada bulan Mei dan pertengahan Juni serta masih ada 5 SKU lagi yang sedang menunggu hasil uji BPOM.
- Perseroan melihat tantangan utama untuk pasar domestik pada 2H23 adalah adanya perubahan perilaku pelanggan serta lemahnya daya beli konsumen. Selain itu, ketidakstabilan nilai tukar di Nigeria memiliki dampak negatif pada kinerja ekspor 2H23. Perlu diketahui, keadaan di Nigeria cukup berpengaruh signifikan terhadap pendapatan ekspor karena porsi ekspor ke Nigeria tercatat sebesar 30% dari total ekspor.
- Di lain sisi, Perseroan juga akan terus melakukan strategi jangka panjangnya, seperti fokus pada branding untuk beberapa produk barunya (RTD dan Esemag) melalui peningkatan investasi dan edukasi produk, penambahan distributor baru di Filipina sudah mulai beroperasi sejak Mei 2023 dan diharapkan akan beroperasi penuh pada 2H23, selain itu bisnis minyak atsiri yang juga aktif menjajaki peluang di pasar domestik untuk memperluas portofolio klien.

Rekomendasi OVERWEIGHT dengan TP Rp700

- Kami memberikan rekomendasi overweight untuk SIDO dengan menurunkan target price menjadi Rp700/saham. TP ini mengimplikasikan P/E sebesar 18,4x (P/E -1 STD) dengan potensi kenaikan sebesar 9,4%. Adapun risiko dari rekomendasi kami yaitu penurunan permintaan produk akibat adanya perubahan perilaku konsumen dan lemahnya daya beli masyarakat.

PT Sido Muncul Tbk | Summary (IDR Bn)

| | 2022A | 2023F | 2024F | 2025F |
|----------------|--------|-------|-------|-------|
| Sales | 3,866 | 3,920 | 4,311 | 4,483 |
| Growth | -3.9% | 1.4% | 10.0% | 4.0% |
| Net Profit | 1,105 | 1,107 | 1,285 | 1,318 |
| Growth | -12.4% | 0.2% | 16.0% | 2.6% |
| EPS (IDR) | 37 | 37 | 43 | 44 |
| P/E | 20.5x | 19.0x | 16.3x | 15.9x |
| P/BV | 6.5x | 6.0x | 5.6x | 5.3x |
| EV/EBITDA | 14.7x | 12.9x | 11.5x | 11.2x |
| ROE | 31.5% | 31.5% | 34.1% | 33.5% |
| ROA | 27.1% | 26.2% | 29.1% | 28.7% |
| Dividend Yield | 4.8% | 5.2% | 5.0% | 5.5% |

Source: Company Data, Bloomberg, NHKSI Research
Please consider the rating criteria & important disclaimer

OVERWEIGHT

| | |
|-----------------------|-------|
| Price Target (IDR) | 700 |
| Consensus Price (IDR) | 761 |
| TP to Consensus Price | -8.1% |
| Potential Upside | 9.4% |

Shares data

| | |
|------------------------|----------------|
| Last Price (IDR) | 640 |
| Price Date as of | August 1, 2023 |
| 52 wk Range (Hi/Lo) | 915/630 |
| Free Float (%) | 22.4 |
| Outstanding sh.(mn) | 30,000 |
| Market Cap (IDR bn) | 19,200 |
| Market Cap (USD mn) | 1,270 |
| Avg. Trd Vol - 3M (mn) | 30.1 |
| Avg. Trd Val - 3M (bn) | 21.6 |
| Foreign Ownership (%) | 26.1 |

Healthcare

Pharmaceutical

| | |
|-----------|---------|
| Bloomberg | SIDO IJ |
| Reuters | SIDO.IK |

Share Price Performance



| | YTD | 1M | 3M | 12M |
|-----------|--------|--------|--------|--------|
| Abs. Ret. | -15.2% | -11.7% | -19.5% | -19.0% |
| Rel. Ret. | -15.8% | -14.6% | -19.8% | -17.5% |


Cindy Alicia Ramadhania

(021) 5088 9129

cindy.alicia@nhsec.co.id


Performance Highlights

SIDO's Revenue Breakdown (2Q23)



Source: Company Data, NHKSI Research

SIDO's Revenue by Segments (IDR Bn)




Source: Company Data, NHKSI Research

SIDO's Revenue Growth



Source: Company Data, NHKSI Research

SIDO's Margin Ratio



Source: Company Data, NHKSI Research

Forward P/E Band



Source: Company Data, NHKSI Research

Dynamic Forward P/E Band



Source: Company Data, NHKSI Research

Summary of Financials

INCOME STATEMENT

| (IDR bn) | 2022/12A | 2023/12E | 2024/12E | 2025/12E |
|---------------------|--------------|--------------|--------------|--------------|
| Net Sales | 3,866 | 3,920 | 4,311 | 4,483 |
| Growth | -3.9% | 1.4% | 10.0% | 4.0% |
| COGS | (1,703) | (1,762) | (1,881) | (1,957) |
| Gross Profit | 2,163 | 2,157 | 2,430 | 2,526 |
| Gross Margin | 55.9% | 55.0% | 56.4% | 56.4% |
| Operating Expenses | (779) | (731) | (821) | (876) |
| EBIT | 1,384 | 1,426 | 1,610 | 1,650 |
| EBIT Margin | 35.8% | 36.4% | 37.3% | 36.8% |
| Depreciation | 95 | 103 | 103 | 107 |
| EBITDA | 1,479 | 1,529 | 1,713 | 1,757 |
| EBITDA Margin | 38.3% | 39.0% | 39.7% | 39.2% |
| Interest Expenses | - | - | - | - |
| EBT | 1,420 | 1,423 | 1,648 | 1,691 |
| Income Tax | (315) | (316) | (363) | (374) |
| Minority Interest | - | - | - | - |
| Net Profit | 1,105 | 1,107 | 1,285 | 1,318 |
| Growth | -12.4% | 0.2% | 16.0% | 2.6% |
| Net Profit Margin | 28.6% | 28.3% | 29.8% | 29.4% |

PROFITABILITY & STABILITY

| | 2022/12A | 2023/12E | 2024/12E | 2025/12E |
|---------------------|----------|----------|----------|----------|
| ROE | 31.5% | 31.5% | 34.1% | 33.5% |
| ROA | 27.1% | 26.2% | 29.1% | 28.7% |
| Inventory Turnover | 3.4x | 4.3x | 4.9x | 4.3x |
| Receivable Turnover | 5.7x | 5.7x | 5.7x | 5.7x |
| Payables Turnover | 8.6x | 8.4x | 8.5x | 8.8x |
| Dividend Yield | 4.8% | 5.2% | 5.0% | 5.5% |
| Payout Ratio | 0.0% | 0.0% | 0.0% | 0.0% |
| DER | 0.0x | 0.0x | 0.0x | 0.0x |
| Net Gearing | 0.0x | 0.0x | 0.0x | 0.0x |
| Equity Ratio | 85.9% | 83.1% | 85.3% | 85.5% |
| Debt Ratio | 0.1% | 0.2% | 0.2% | 0.2% |
| Financial Leverage | 104.7% | 100.1% | 96.6% | 100.2% |
| Current Ratio | 4.1x | 3.5x | 4.2x | 4.3x |
| Quick Ratio | 3.1x | 2.7x | 3.5x | 3.6x |
| Par Value (IDR) | 10 | 10 | 10 | 10 |
| Total Shares (mn) | 30,000 | 30,000 | 30,000 | 30,001 |
| Share Price (IDR) | 755 | 700 | 700 | 700 |
| Market Cap (IDR tn) | 22.7 | 21.0 | 21.0 | 21.0 |

BALANCE SHEET

| (IDR bn) | 2022/12A | 2023/12E | 2024/12E | 2025/12E |
|----------------------------------|--------------|--------------|--------------|--------------|
| Cash | 923 | 1,240 | 1,331 | 1,374 |
| Receivables | 687 | 551 | 753 | 783 |
| Inventories | 543 | 531 | 383 | 450 |
| Total Current Assets | 2,194 | 2,372 | 2,513 | 2,655 |
| Net Fixed Assets | 1,616 | 1,611 | 1,657 | 1,683 |
| Other Non Current Assets | 271 | 243 | 246 | 254 |
| Total Non Current Asset | 1,887 | 1,855 | 1,903 | 1,937 |
| Total Assets | 4,081 | 4,227 | 4,416 | 4,592 |
| Payables | 209 | 149 | 220 | 221 |
| ST Bank Loan | 2 | 3 | 2 | 2 |
| Total Current Liabilities | 541 | 671 | 603 | 621 |
| LT Debt | - | 5 | 5 | 5 |
| Total Liabilities | 576 | 713 | 649 | 664 |
| Capital Stock & APIC | 2,152 | 2,152 | 2,152 | 2,152 |
| Retained Earnings | 1,354 | 1,362 | 1,615 | 1,777 |
| Shareholders' Equity | 3,505 | 3,513 | 3,767 | 3,928 |

CASH FLOW STATEMENT

| (IDR bn) | 2022/12A | 2023/12E | 2024/12E | 2025/12E |
|----------------------------|--------------|------------|-----------|-----------|
| Operating Cash Flow | 1,107 | 1,505 | 1,271 | 1,343 |
| Investing Cash Flow | (180) | (91) | (128) | (144) |
| Financing Cash Flow | (1,088) | (1,098) | (1,052) | (1,156) |
| Net Changes in Cash | (159) | 317 | 91 | 43 |

Source: Company Data, NHKSI Research

VALUATION INDEX

| | 2022/12A | 2023/12E | 2024/12E | 2025/12E |
|------------------------|----------|----------|----------|----------|
| Price /Earnings | 20.5x | 19.0x | 16.3x | 15.9x |
| Price /Book Value | 6.5x | 6.0x | 5.6x | 5.3x |
| PE/EPS Growth | -1.7x | 76.4x | 1.0x | 6.2x |
| EV/EBITDA | 14.7x | 12.9x | 11.5x | 11.2x |
| EV/EBIT | 15.7x | 13.9x | 12.2x | 11.9x |
| EV (IDR bn) | 21,729 | 19,768 | 19,676 | 19,634 |
| Sales CAGR (3-Yr) | 13.3% | 8.0% | 5.5% | 2.4% |
| Net Income CAGR (3-Yr) | 23.8% | 11.0% | 5.8% | 0.6% |
| Basic EPS (IDR) | 37 | 37 | 43 | 44 |
| BVPS (IDR) | 117 | 117 | 126 | 131 |
| DPS (IDR) | 36 | 36 | 35 | 39 |

OWNERSHIP

| Shareholders | % |
|---|------|
| PT HOTEL CANDI BARU | 60.5 |
| CONCORDANT INVESTMENTS LP | 17.1 |
| PT Schroder Investment Management Indonesia | 1.3 |
| Blackrock Inc | 0.6 |
| By Geography | % |
| Unknown | 92.9 |
| Indonesia | 1.9 |
| United States | 1.7 |
| Luxembourg | 1.1 |

NH Korindo Sekuritas Indonesia (NHKSI) Stock Ratings

1. Based on a stock's forecasted absolute return over a period of 12 months from the date of publication.
2. Rating system based on a stock's potential upside from the date of publication
 - Buy : Greater than +15%
 - Overweight : +5% to 15%
 - Hold : -5% to +5%
 - Underweight : -5% to -15%
 - Sell : Less than -15%

DISCLAIMER

This document is strictly confidential and is being supplied to you solely for your information. The recipients of this report must make their own independent decisions regarding any securities or financial instruments mentioned herein. This document may not be quoted, reproduced, exhibited, redistributed, transmitted, edited, translated, or published, in whole or in part, for any purpose without notice. Any failure to comply with this restriction may constitute a violation of civil or criminal laws.

This report and any electronic access hereto are restricted and intended only for the clients and related entities of PT NH Korindo Sekuritas Indonesia. This report is only for information and recipient use. It is not reproduced, copied, or made available for others. Under no circumstances is it considered as a selling offer or solicitation of securities buying. Any recommendation contained herein may not be suitable for all investors. Although the information hereof is obtained from reliable sources, its accuracy and completeness cannot be guaranteed. PT NH Korindo Sekuritas Indonesia, its affiliated companies, employees, and agents are held harmless from any responsibility and liability for claims, proceedings, action, losses, expenses, damages, or costs filed against or suffered by any person as a result of acting pursuant to the contents hereof. Neither is PT NH Korindo Sekuritas Indonesia, its affiliated companies, employees, nor agents are liable for errors, omissions, misstatements, negligence, inaccuracy contained herein. All rights reserved by PT NH Korindo Sekuritas Indonesia.